Covestor’s Maze Therapeutics MAZE Stock Holding History

Covestor’s Portfolio MAZE Stock Details MAZE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	12 +9	+300%	+$236	﹤0.01%	2908
2026 Q1	$0	Buy	+3	New	+$132	﹤0.01%	2884

Other funds holding MAZE

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Covestor's MAZE Position: Q2 2026 in Review

Covestor increased its Maze Therapeutics (MAZE) stake by 300% in Q2 2026, buying an estimated $236 and bringing the position to 12 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2908.

Covestor first reported a position in MAZE in Q1 2026 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

Covestor held 12 shares of Maze Therapeutics worth $0 as of Q2 2026.
Covestor bought 9 Maze Therapeutics shares in Q2 2026, an estimated $236.
Maze Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2908 holding.
Covestor first reported a position in Maze Therapeutics in Q1 2026 and has held it in 2 quarters since.
162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.